Pancreatic disease

THE PANCREATIC CANCER ACTION NETWORK (PANCAN) APPOINTS NEW CHAIR AND WELCOMES NEW MEMBER TO ITS BOARD OF DIRECTORS

Retrieved on: 
Tuesday, July 12, 2022

LOS ANGELES, July 12, 2022 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic cancer, has appointed Michael Korengold, president and CEO of Enhanced Capital Partners, as chair of its board of directors. Additionally, the organization has welcomed Linda Amuso, Senior Partner at Aon in the Human Capital Practice, as a new board member. These leadership updates bring added expertise to the national organization, where bold action is leading the way to accelerate progress for pancreatic cancer patients and create a world in which they thrive.

Key Points: 
  • Additionally, the organization has welcomed Linda Amuso, Senior Partner at Aon in the Human Capital Practice, as a new board member.
  • Each member has been personally impacted by pancreatic cancer.
  • Korengold lost his mother to the disease in 1995 and Amuso's wife passed away in 2016, following a nearly two-and-a-half-year battle with pancreatic cancer.
  • The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients.

The National Pancreas Foundation Launches First Real-Time Patient Registry Powered by SeqsterOS

Retrieved on: 
Monday, May 23, 2022

The National Pancreas Foundation ("NPF"), a nonprofit organization that provides hope for those suffering from pancreatitis and pancreatic cancer, announced today at Digestive Disease Week 2022 in San Diego, the launch of the country's largest, most inclusive pancreatic disease patient registry powered by SeqsterOS .

Key Points: 
  • The National Pancreas Foundation ("NPF"), a nonprofit organization that provides hope for those suffering from pancreatitis and pancreatic cancer, announced today at Digestive Disease Week 2022 in San Diego, the launch of the country's largest, most inclusive pancreatic disease patient registry powered by SeqsterOS .
  • "Now, we can enable greater collaboration amongst researchers and our foundation, improve the quality of patient care, and significantly impact outcomes for patients with pancreatic disease."
  • "There is no better conference than DDW for NPF to announce their patient registry powered by SeqsterOS," exclaimed Ardy Arianpour, CEO & Co-Founder of Seqster.
  • "The NPF registry with SeqsterOS tackles traditional hurdles faced by patient registries from two angles: nationwide interoperability and patient engagement.

Innovative AI software for the detection of pancreatic diseases: first-in-human application successful

Retrieved on: 
Monday, May 16, 2022

In Europe today, more than 90 percent of patients die of pancreatic cancer within the first five years after diagnosis.

Key Points: 
  • In Europe today, more than 90 percent of patients die of pancreatic cancer within the first five years after diagnosis.
  • As part of large-scale clinical studies prior to market introduction, the AI software has now gone into clinical test with patients, so-called first-in-human applications.
  • View the full release here: https://www.businesswire.com/news/home/20220516005559/en/
    The new AI software has the potential to revolutionize the diagnosis of pancreatic diseases.
  • Photo: Medi-Globe Group
    The new software has the potential to revolutionize the diagnosis of pancreatic diseases and, above all, the diagnosis of pancreatic cancer.

The National Pancreas Foundation Partners with Seqster to Launch a New Dynamic Patient Registry System

Retrieved on: 
Tuesday, January 11, 2022

The innovative new registry powered by Seqster connects to any EHR, genomic DNA test, and wearable/remote monitoring device, providing patients with a complete longitudinal health record in real-time.

Key Points: 
  • The innovative new registry powered by Seqster connects to any EHR, genomic DNA test, and wearable/remote monitoring device, providing patients with a complete longitudinal health record in real-time.
  • "We are very excited to enter a multi-year partnership with Seqster to create a one-of-a-kind patient registry," said CEO at NPF, David Bakelman
    "We are very excited to enter a multi-year partnership with Seqster to create a one-of-a-kind patient registry that truly empowers our members.
  • Without the Seqster technology, this would have never been possible," said Chief Executive Officer at NPF, David Bakelman.
  • "Now, we can enable greater collaboration amongst researchers and our foundation, improve the quality of patient care, and significantly impact outcomes for patients with pancreatic disease."

Gregg A. Valenzuela is recognized by Continental Who's Who

Retrieved on: 
Tuesday, January 4, 2022

ALBUQUERQUE, N.M., Jan. 4, 2022 /PRNewswire/ --Gregg A. Valenzuela is being recognized by Continental Who's Who as a Trusted Gastroenterologist for his years as an accomplished medical provider.

Key Points: 
  • ALBUQUERQUE, N.M., Jan. 4, 2022 /PRNewswire/ --Gregg A. Valenzuela is being recognized by Continental Who's Who as a Trusted Gastroenterologist for his years as an accomplished medical provider.
  • With 45 years in the medical field, Dr. Valenzuela is acclaimed for his dedication to his patients.
  • Dr. Valenzuela also completed a Fellowship in Gastroenterology at the University of Virginia Health Sciences Center.
  • When he isn't working, Dr. Valenzuela enjoys Transcendental Meditation, running, traveling with his wife Marielle, and writing poetry.

AzurRx BioPharma Receives Approximately $550K for its 2020 CIR (French Research Tax Credit)

Retrieved on: 
Wednesday, May 12, 2021

These funds have enabled us to successfully run the European arms of our two Phase 2 MS1819 clinical trials - despite the challenges posed by the COVID epidemic.

Key Points: 
  • These funds have enabled us to successfully run the European arms of our two Phase 2 MS1819 clinical trials - despite the challenges posed by the COVID epidemic.
  • It is particularly adapted to the needs of small and medium-sized enterprises.\nAzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
  • The lead therapeutic drug candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.
  • For more information visit www.azurrx.com .\nThis press release may contain certain statements relating to future results which are forward-looking statements.

AzurRx BioPharma to Report Topline Data from Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

Retrieved on: 
Wednesday, March 31, 2021

ET, to discuss the topline results from its Phase 2b OPTION 2 clinical trial investigating MS1819 in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI).

Key Points: 
  • ET, to discuss the topline results from its Phase 2b OPTION 2 clinical trial investigating MS1819 in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI).
  • An audio webcast of the conference call will be accessible via the Investors section of the AzurRx website https://azurrx.com/.
  • The OPTION 2 trial was an open-label, crossover study, conducted in 15 sites in the U.S. and Europe.
  • MS1819 is a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis.

Exocrine Pancreatic Insufficiency Market Anticipated to Soar Modestly with a CAGR 7.21% During the Study Period 2018-30 in the 7MM, Estimates DelveInsight

Retrieved on: 
Wednesday, March 24, 2021

The Exocrine Pancreatic Insufficiency market size is expected to expand owing to factors like increasing EPI prevalent population, entry of Exocrine Pancreatic Insufficiency emerging therapies with novel targets and attractive pricing.

Key Points: 
  • The Exocrine Pancreatic Insufficiency market size is expected to expand owing to factors like increasing EPI prevalent population, entry of Exocrine Pancreatic Insufficiency emerging therapies with novel targets and attractive pricing.
  • Request for sample @ Exocrine Pancreatic Insufficiency Market Insights, and Forecast
    The Exocrine Pancreatic Insufficiency market report proffers a detailed analysis of treatment landscape, pipeline therapies, changing market landscape, individual market share of pipeline therapies, EPI market drivers, and market barriers, EPI market size during the study period 2018-30 in the 7MM).
  • Exocrine Pancreatic Insufficiency or Pancreatic exocrine insufficiency (PEI/EPI) is defined as inadequate activity or deficiency of the pancreatic enzymes within the intestinal lumen, resulting in maldigestion and malabsorption.
  • Pancreatic enzyme replacement therapy (PERT) is the first-line therapeutic mainstay of the Exocrine Pancreatic Insufficiency therapeutics market.

Exocrine Pancreatic Insufficiency Market Anticipated to Soar Modestly with a CAGR 7.21% During the Study Period 2018-30 in the 7MM, Estimates DelveInsight

Retrieved on: 
Wednesday, March 24, 2021

The Exocrine Pancreatic Insufficiency market size is expected to expand owing to factors like increasing EPI prevalent population, entry of Exocrine Pancreatic Insufficiency emerging therapies with novel targets and attractive pricing.

Key Points: 
  • The Exocrine Pancreatic Insufficiency market size is expected to expand owing to factors like increasing EPI prevalent population, entry of Exocrine Pancreatic Insufficiency emerging therapies with novel targets and attractive pricing.
  • Request for sample @ Exocrine Pancreatic Insufficiency Market Insights, and Forecast
    The Exocrine Pancreatic Insufficiency market report proffers a detailed analysis of treatment landscape, pipeline therapies, changing market landscape, individual market share of pipeline therapies, EPI market drivers, and market barriers, EPI market size during the study period 2018-30 in the 7MM).
  • Exocrine Pancreatic Insufficiency or Pancreatic exocrine insufficiency (PEI/EPI) is defined as inadequate activity or deficiency of the pancreatic enzymes within the intestinal lumen, resulting in maldigestion and malabsorption.
  • Pancreatic enzyme replacement therapy (PERT) is the first-line therapeutic mainstay of the Exocrine Pancreatic Insufficiency therapeutics market.

AzurRx BioPharma Announces Completion of Enrollment in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

Retrieved on: 
Monday, March 22, 2021

We are very pleased to have completed enrollment in our Phase 2 MS1819 plus PERT combination therapy clinical trial, said James Sapirstein, President, CEO and Chairman of AzurRx.

Key Points: 
  • We are very pleased to have completed enrollment in our Phase 2 MS1819 plus PERT combination therapy clinical trial, said James Sapirstein, President, CEO and Chairman of AzurRx.
  • We continue to remain on target to report topline results from the combination therapy study during the second quarter of 2021.
  • MS1819 is a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis.
  • The lead therapeutic candidate isMS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis,currently in two Phase 2 clinical trials.